Publications en collaboration avec des chercheurs de Duke University (5)

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2017

  1. Transancestral mapping and genetic load in systemic lupus erythematosus

    Nature Communications, Vol. 8

2016

  1. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    Journal of the American Heart Association, Vol. 5, Núm. 9

2013

  1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    New England Journal of Medicine, Vol. 369, Núm. 14, pp. 1317-1326